The pharmaceutical industry is highly dependent on small innovator companies to fill late-stage pipeline needs. As a result, innovators are focused on achieving hPOC to monetize their development investment through a transaction with a biopharma partner or an IPO.

The Goal for These Companies and Their Investors is Simple:

• Accelerate drug development
• Minimize spend
• Avoid building excess infrastructure

With the end result being a high-quality hPOC data package required by regulatory agencies and potential biopharma partners.

What is our solution? Our approach to development is an asset-centric alternative to traditional high risk, cash intensive, time-consuming approaches. Uniphar (formerly RRD) integrates all critical development disciplines including strategy, regulatory, clinical, quality, and CMC.

How do we do this? Uniphar's (formerly RRD) Product Development Team (PDT) partnering model enables development of high-quality data packages compliant with regulatory requirements. Uniphar's model is designed to achieve our partner's goals, whether the goal is to close a successful deal with a biopharma partner, or to obtain FDA/EMA marketing approval. We are driven to build value for our partners and investors, and ultimately to bring new medicines to patients.

We work closely with partners to effectively and efficiently optimize asset value and quantify product potential regardless of an organization’s stage of development:

• For innovators, we accelerate achievement of an asset’s hPOC value inflection point, significantly increasing an asset’s desirability to potential partners looking for late-stage clinical assets for development and commercialization
• For established companies with multiple assets, we help expand pipelines with high quality, de-risked NCE or 505(b)(2) assets with demonstrated hPOC without the need to invest in additional fixed-cost infrastructure